Robert Thomas Freeman Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 6 days ago
Robert Thomas Freeman has an estimated net worth of at least $23.0 million*, as of Nov. 13, 2024. They own 958,336 shares of ALHC stock. They have sold 822,276 shares of ALHC stock since 2021, for an estimated $10.0 million.
Robert Thomas Freeman $ALHC SEC Form 4 Insider Trading
Robert Thomas Freeman has filed a total of 40 insider trades in $ALHC since 2021. Their most recent trade was a sale of 30,500 shares, made on Nov 11, 2024. Their largest trade was a sale of 120,500 shares, made on Sep 12, 2024. We estimate that they now own 958,336 shares of $ALHC, worth an estimated $13.0 million.
Insider Trading at $ALHC
There have been a total of 193 insider trades reported at $ALHC since 2021, with 203,000 shares purchased and 48.9 million shares sold. The most active insider traders in $ALHC stock have been Robert Thomas Freeman, Dawn Christine Maroney, and John E Kao. The most recent trade was a sale of 30,000 shares reported by Dawn Christine Maroney (President, Markets), made on Nov 15, 2024.
History of Insider Stock Trades by Robert Thomas Freeman
Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
---|---|---|---|---|
ALHC | Sale | 30,500 | Nov 11, 2024 | Nov. 13, 2024, 6:16 p.m. |
ALHC | Sale | 36,197 | Oct 31, 2024 | Oct. 31, 2024, 6:11 p.m. |
ALHC | Sale | 4,483 | Oct 29, 2024 | Oct. 31, 2024, 6:11 p.m. |
ALHC | Sale | 30,500 | Oct 14, 2024 | Oct. 16, 2024, 5:37 p.m. |
ALHC | Sale | 39,320 | Oct 08, 2024 | Oct. 10, 2024, 6:56 p.m. |
ALHC | Sale | 12,200 | Oct 01, 2024 | Oct. 3, 2024, 6:17 p.m. |
ALHC | Sale | 9,175 | Oct 01, 2024 | Oct. 3, 2024, 6:17 p.m. |
ALHC | Sale | 9,125 | Oct 02, 2024 | Oct. 3, 2024, 6:17 p.m. |
ALHC | Sale | 120,500 | Sep 12, 2024 | Sept. 13, 2024, 6:19 p.m. |
ALHC | Sale | 14,500 | Sep 13, 2024 | Sept. 13, 2024, 6:19 p.m. |
ALHC | Sale | 8,561 | Sep 11, 2024 | Sept. 13, 2024, 6:19 p.m. |
ALHC | Sale | 1,640 | Sep 04, 2024 | Sept. 6, 2024, 5:28 p.m. |
ALHC | Sale | 10 | Sep 04, 2024 | Sept. 6, 2024, 5:28 p.m. |
ALHC | Sale | 4,789 | Sep 05, 2024 | Sept. 6, 2024, 5:28 p.m. |
ALHC | Sale | 22,100 | Jul 17, 2024 | July 19, 2024, 8:22 p.m. |
ALHC | Sale | 44,042 | Jul 18, 2024 | July 19, 2024, 8:22 p.m. |
ALHC | Sale | 38,858 | Jul 19, 2024 | July 19, 2024, 8:22 p.m. |
ALHC | Sale | 4,299 | Mar 28, 2024 | March 29, 2024, 8 p.m. |
ALHC | Sale | 28,522 | Mar 19, 2024 | March 21, 2024, 5 p.m. |
ALHC | Sale | 11,858 | Mar 15, 2024 | March 15, 2024, 8 p.m. |
ALHC | Sale | 5,312 | Mar 29, 2023 | March 31, 2023, 5 p.m. |
ALHC | Sale | 3,290 | Mar 31, 2023 | March 31, 2023, 5 p.m. |
ALHC | Sale | 13,470 | Mar 14, 2023 | March 15, 2023, 6 p.m. |
ALHC | Sale | 1,100 | Jan 18, 2023 | Jan. 20, 2023, 7 p.m. |
ALHC | Sale | 24,000 | Dec 01, 2022 | Dec. 2, 2022, 8:26 p.m. |
ALHC | Sale | 24,000 | Nov 01, 2022 | Nov. 2, 2022, 4:27 p.m. |
ALHC | Sale | 24,000 | Oct 26, 2022 | Oct. 28, 2022, 4:25 p.m. |
ALHC | Sale | 24,000 | Sep 01, 2022 | Sept. 2, 2022, 4:10 p.m. |
ALHC | Sale | 40,497 | Aug 05, 2022 | Aug. 9, 2022, 12:32 p.m. |
ALHC | Sale | 2,913 | Aug 05, 2022 | Aug. 9, 2022, 12:32 p.m. |
ALHC | Sale | 24,000 | Aug 01, 2022 | Aug. 2, 2022, 9:21 p.m. |
ALHC | Sale | 20,383 | Jul 05, 2022 | July 7, 2022, 6:51 p.m. |
ALHC | Sale | 12,000 | Jul 01, 2022 | July 1, 2022, 7:04 p.m. |
ALHC | Sale | 100 | Jun 22, 2022 | June 22, 2022, 8 p.m. |
ALHC | Sale | 3,517 | Jun 21, 2022 | June 22, 2022, 8 p.m. |
ALHC | Sale | 12,000 | Jun 17, 2022 | June 17, 2022, 5:55 p.m. |
ALHC | Sale | 4,944 | Mar 31, 2022 | April 1, 2022, 7:14 p.m. |
ALHC | Sale | 3,292 | Apr 01, 2022 | April 1, 2022, 7:14 p.m. |
ALHC | Sale | 85,279 | Nov 23, 2021 | Nov. 24, 2021, 7:31 p.m. |
ALHC | Sale | 23,000 | Oct 20, 2021 | Oct. 21, 2021, 8 p.m. |
$ALHC Executives and Stock Owners with Insider Trades
-
Robert Thomas Freeman, Chief Financial Officer
-
Dawn Christine Maroney, President, Markets
-
John E Kao, Chief Executive Officer
-
Dinesh M. Kumar, Chief Med & Operating Officer
-
Christopher J Joyce, Chief Legal and Admin. Officer
-
Hakan Kardes, Chief Experience Officer
-
Dinesh M. Kumar, Chief Medical Officer
-
Joseph S Konowiecki, Chairman of the Board
-
Richard A. Cross, SVP, General Counsel
-
Robert L. Scavo, Chief Information Officer
-
Donald Steven Furman, Chief Clinical Officer
-
Hyong Kim, Chief Medical Officer
-
Rajesh Shrestha, Pres., New Markets & CBO
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.